CoordenaÃÃo de AperfeÃoamento de Pessoal de NÃvel Superior / Oxaliplatina (OXL) à um composto de platina de terceira geraÃÃo com potente atividade citotÃxica contra vÃrios tipos de cÃncer, possuindo um efeito colateral de difÃcil tratamento, uma severa neuropatia perifÃrica. Estudos sugerem que o oxalato, metabÃlito da OXL, està envolvido no desenvolvimento dessa neuropatia sensitiva perifÃrica (NSP); de modo que foi publicada a sÃntese de um anÃlogo (LLC-1402) da OXL, livre de oxalato, tendo propriedades antitumorais (LIU et al., 2013). O objetivo do trabalho à estudar o papel do oxalato na neuropatia induzida por OXL em camundongos, comparando a OXL com LLC-1402. A NSP foi induzida por 2 injeÃÃes (iv.) por semana de OXL (2 mg/kg), em camundongos machos Swiss, durante 4  semanas, totalizando 9 injeÃÃes. LLC-1402 (7, 14 e 28 mg/kg) foi administrado (iv.) seguindo o mesmo esquema. Foram realizados testes nociceptivos (Von Frey eletrÃnico e TIC), semanalmente. Depois, foi escolhida a dose de 14 mg/kg do LLC-1402 para fazer um outro experimento, no qual foi acrescentada a injeÃÃo ip. de oxalato (1,7 mg/kg). No 28 dia, foi feita coleta de sangue para contagem total de leucÃcitos e dosagens bioquÃmicas. Nos 28 e 56 dias, foi feita a coleta de medula espinhal e GRD para imunofluorescÃncia para ATF-3, c-FOS, iNOS e NeuN. Os resultados mostraram que a OXL e o LLC-1402 foram capazes de diminuir o limiar de retirada da pata e o tempo de retirada da cauda significativamente (p<0,05), comparado ao grupo controle. A injeÃÃo de LLC-1402 junto com oxalato e somente oxalato tambÃm foi capaz de reduzir o limiar de retirada da pata e o tempo de retirada da cauda. Os grupos tratados com OXL, LLC-1402 e oxalato mostraram uma reduÃÃo significativa da contagem total de leucÃcitos. Para as dosagens bioquÃmicas (TGO, TGP, ureia, creatinina), nÃo houve diferenÃa estatÃstica entre os grupos. Houve um aumento da imunoexpressÃo de c-Fos no GRD nos grupos tratados com OXL, LLC-1402 e LLC-1402 junto com oxalato nos 28 e 56 dias, e somente oxalato no 28 dia. Foi observado esse aumento no corno dorsal da medula espinhal no 28 dia em todos os grupos tratados. Foi observado um aumento da imunoexpressÃo de ATF-3, no GRD e corno dorsal da medula espinhal, em todos os grupos tratados, nos 28 e 56 dias. NÃo houve diferenÃa significativa entre os grupos no GRD nem medula espinhal na imunoexpressÃo de iNOS no 56 dia; jÃ, no 28 dia, houve um aumento da imunoexpressÃo de iNOS no GRD. Os resultados mostraram que o oxalato pode estar envolvido parcialmente na NSP induzida por OXL. / Oxaliplatin (OXL) is a third generation platinum compound with potent cytotoxic activity against several types of cancers, having a side effect is difficult to treat, a severe peripheral neuropathy. Studies suggest that oxalate, OXL metabolite, is involved in the development of peripheral sensory neuropathy (PSN); so that was published the synthesis of an OXL analogue (LLC-1402), oxalate free, which has antitumor properties (LIU et al., 2013). The objective of this research is to study the role of oxalate in OXL induced neuropathy in mice, comparing OXL with LLC-1402. The PSN was induced by two injections (iv.) OXL (2 mg/ kg) per week, in male Swiss mice, for 4  weeks, totaling 9 injections. LLC-1402 (7, 14 and 28 mg / kg) was administered (iv.) following the same scheme. Nociceptive tests were performed (electronic von Frey and tail immersion test) weekly. After, it was chosen dose of 14 mg / kg of the LLC-1402 to perform another experiment, in which was added oxalate injection (1.7 mg/kg). In the 28th day, it was made blood collection for total leukocyte count and biochemical measurement. In the 28th and 56th days, spinal cord and DRG were removed for immunofluorescence for ATF-3, c-FOS, iNOS and NeuN. The results showed that both OXL and LLC-1402 were able to decrease the paw withdrawal threshold and tail withdrawal time significantly (p<0.05) compared to the control group. The injection of LLC-1402 together with oxalate and only oxalate was also able to reduce the paw withdrawal threshold and the tail withdrawal time. Moreover, all groups treated with OXL, LLC-1402 and oxalate showed a significant reduction in the total leukocyte count. The biochemical measurement (glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, urea, creatinine) showed no statistical difference between the groups. The results also showed increased c-Fos immunoexpression in GRD in groups treated with OXL, LLC-1402 and LLC-1402 together with oxalate in the 28 and 56 days, and only oxalate the 28th day. This increase was observed in the dorsal horn of the spinal cord at 28th day in all the treated groups. It was not observed this increase in the dorsal horn of the spinal cord in the 56th day. It was observed an increase in immunoexpression of ATF3 in DRG and spinal cord of dorsal horn in all treated groups in the 28th and 56th days. iNOS immunofluorescence showed no significant difference between groups in the DRG nor spinal cord, already in the 28th day, there was an increase in immunoexpression of iNOS in GRD. Thus, the results showed that the oxalate may be partially involved in PSN induced OXL.
| Identifer | oai:union.ndltd.org:IBICT/oai:www.teses.ufc.br:10364 |
| Date | 08 October 2015 |
| Creators | Anamaria FalcÃo Pereira |
| Contributors | Mariana Lima Vale, Marcelo Leite Vieira Costa, Carlos Campos CÃmara |
| Publisher | Universidade Federal do CearÃ, Programa de PÃs-GraduaÃÃo em Farmacologia, UFC, BR |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UFC, instname:Universidade Federal do Ceará, instacron:UFC |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.003 seconds